Albireo Pharma Inc.

21.16-1.73-7.56%Vol 924.62K1Y Perf -25.24%
May 18th, 2022 16:00 DELAYED
BID18.39 ASK22.10
Open22.43 Previous Close22.89
Pre-Market- After-Market21.14
 - -  -0.02 -0.09%
Target Price
73.75 
Analyst Rating
Strong Buy 1.00
Potential %
248.54 
Finscreener Ranking
★★★★★     62.62
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     56.98
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     66.09
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
4.90 
Earnings Rating
Sell
Market Cap414.02M 
Earnings Date
16th May 2022
Alpha0.01 Standard Deviation0.14
Beta0.95 

Today's Price Range

20.5422.43

52W Range

20.3037.86

5 Year PE Ratio Range

-6.00-1.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-16.58%
1 Month
-33.86%
3 Months
-29.46%
6 Months
-8.37%
1 Year
-25.24%
3 Years
-36.38%
5 Years
6.32%
10 Years
-70.65%

TickerPriceChg.Chg.%
ALBO21.16-1.7300-7.56
AAPL140.82-8.4200-5.64
GOOG2 248.02-86.0100-3.69
MSFT254.08-12.1200-4.55
XOM90.65-1.4600-1.59
WFC42.11-1.6000-3.66
JNJ175.50-3.3200-1.86
FB192.24-10.3800-5.12
GE75.20-1.2000-1.57
JPM120.09-2.0900-1.71
Financial StrengthValueIndustryS&P 500US Markets
5.50
5.90
0.05
0.06
-1.40
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
96.70
-49.50
-48.90
-484 511.00
21.67
RevenueValueIndustryS&P 500US Markets
38.61M
1.97
139.27
157.90
Earnings HistoryEstimateReportedSurprise %
Q01 2022-2.02-2.19-8.42
Q04 2021-1.27-0.5755.12
Q03 20210.54-1.26-333.33
Q02 2021-1.92-1.901.04
Q01 2021-1.72-2.29-33.14
Q04 2020-1.90-1.3031.58
Q03 2020-1.48-1.96-32.43
Q02 2020-1.65-1.3816.36
Earnings Per EndEstimateRevision %Trend
3/2022 QR-2.02-19.53Negative
6/2022 QR-1.93-26.97Negative
12/2022 FY-7.11-11.09Negative
12/2023 FY-4.00-39.86Negative
Next Report Date-
Estimated EPS Next Report-2.02
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume924.62K
Shares Outstanding19.57K
Shares Float14.71M
Trades Count11.98K
Dollar Volume19.57M
Avg. Volume401.51K
Avg. Weekly Volume607.64K
Avg. Monthly Volume293.67K
Avg. Quarterly Volume303.24K

Albireo Pharma Inc. (NASDAQ: ALBO) stock closed at 22.89 per share at the end of the most recent trading day (a -18.37% change compared to the prior day closing price) with a volume of 2.04M shares and market capitalization of 414.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Albireo Pharma Inc. CEO is Ronald H.W. Cooper.

The one-year performance of Albireo Pharma Inc. stock is -25.24%, while year-to-date (YTD) performance is -1.72%. ALBO stock has a five-year performance of 6.32%. Its 52-week range is between 20.3 and 37.86, which gives ALBO stock a 52-week price range ratio of 4.90%

Albireo Pharma Inc. currently has a PE ratio of -15.10, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 14.21, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -11.98%, a ROC of -10.68% and a ROE of -19.77%. The company’s profit margin is 21.67%, its EBITDA margin is -48.90%, and its revenue ttm is $38.61 Million , which makes it $1.97 revenue per share.

Of the last four earnings reports from Albireo Pharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.02 for the next earnings report. Albireo Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Albireo Pharma Inc. is Strong Buy (1), with a target price of $73.75, which is +248.54% compared to the current price. The earnings rating for Albireo Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Albireo Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Albireo Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.60, ATR14 : 2.31, CCI20 : -253.46, Chaikin Money Flow : -0.21, MACD : -1.69, Money Flow Index : 26.78, ROC : -28.06, RSI : 26.08, STOCH (14,3) : 16.42, STOCH RSI : 0.00, UO : 34.76, Williams %R : -83.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Albireo Pharma Inc. in the last 12-months were: Jan P. Mattsson (Sold 1 008 shares of value $26 690 ), Jason G. Duncan (Option Excercise at a value of $396 365), Jason G. Duncan (Sold 19 268 shares of value $674 998 ), Martha Carter (Sold 526 shares of value $13 762 ), Michelle Graham (Sold 521 shares of value $13 725 ), Pamela Stephenson (Sold 2 369 shares of value $70 357 ), Patrick Taylor Horn (Sold 185 shares of value $5 811 ), Ronald H.W. Cooper (Option Excercise at a value of $229 762), Ronald H.W. Cooper (Sold 4 591 shares of value $121 697 ), Simon Nicolas Reade Harford (Sold 917 shares of value $26 297 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Albireo Pharma Inc.

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.

CEO: Ronald H.W. Cooper

Telephone: +1 857 254-5555

Address: 10 Post Office Square, South Boston 02109, MA, US

Number of employees: 90

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

86%14%

Bearish Bullish

67%33%

Bearish Bullish

69%31%

TipRanks News for ALBO

Wed, 13 Apr 2022 14:55 GMT Wedbush Believes Albireo Pharma (ALBO) Still Has Room to Grow

- TipRanks. All rights reserved.

Tue, 29 Mar 2022 15:15 GMT Albireo Pharma (ALBO) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 10:16 GMT Albireo Pharma (ALBO) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 16:05 GMT Albireo Pharma (ALBO) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 11:25 GMT Analysts Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)

- TipRanks. All rights reserved.

News

Stocktwits